Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

By Amira McKee

Vertex Pharmaceuticals logged higher fourth-quarter profit as persistent demand for its cystic fibrosis treatments drove double-digit revenue growth.

The biotechnology company reported a fourth-quarter profit of $1.19 billion, or $4.65 a share, compared with $913 million, or $3.50 a share, a year earlier.

Adjusted earnings came in at $5.03 a share. Analysts polled by FactSet were looking for $5.11 a share.

Revenue grew 10% to $3.19 billion, beating Wall Street's estimate of $3.18 billion, according to FactSet.

The top-line growth was primarily driven by the continued performance of cystic fibrosis therapies and additional growth from diversification into additional disease areas, the company said.

In the U.S., total revenue jumped 12% to $2.06 billion, boosted by strong patient demand for cystic fibrosis therapies, including for Alyftrek. Outside the U.S., total revenue increased 5% to $1.13 billion, helped by higher sales of Casgevy, a treatment for severe sickle cell disease.

For the full year, Vertex guided for revenue of $12.95 billion to $13.1 billion. The outlook, Vertex said, includes expectations for continued growth in cystic fibrosis, including the ongoing U.S. rollout and international launches of Alyftrek. Vertex anticipates that full-year results will also be helped by $500 million or more in revenue from non-cystic fibrosis products.

Wall Street forecast 2026 revenue of $13.02 billion, according to FactSet.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

February 12, 2026 16:47 ET (21:47 GMT)